A Genentech Inc. patent discloses new benzothiazole compounds acting as von Hippel-Lindau disease tumor suppressor (VHL) inhibitors and reported to be useful for the treatment of ischemia, cancer and anemia.
Spark Biomedical Inc. is seeking patent protection for the use of its transcutaneous auricular neurostimulation (tAN) platform for treating stress and improving performance in stressful situations while controlling bleeding.
Idorsia Pharmaceuticals Ltd. researchers have prepared and tested new thiazoloaryl-methyl substituted cyclic hydrazine-N-carboxamide derivatives acting as orexin OX1 and OX2 receptor antagonists. They are reported to be useful for the treatment of substance abuse and dependence, anxiety, cognitive, sleep, eating and mood disorders.
An F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. patent describes indole derivatives acting as EGFR L858R mutant, T790M/L858R double mutant, T790M/L858R/C797S triple mutant and/or L858R/C797S double mutant allosteric inhibitors reported to be useful for the treatment of non-small-cell lung cancer (NSCLC).
Work at Wake Forest University has led to the development of an H2O2-responsive doxorubicin hybrid codrug able to release H2S (acting as cardioprotective agent). They are reported to be useful for the treatment of cancer.
Ventus Therapeutics US Inc. has disclosed oxoindolinyl amide derivatives acting as NLRP3 inflammasome inhibitors. As such, they are reported to be useful for the treatment of cancer, metabolic, autoimmune diseases, liver, renal, respiratory, cardiovascular and inflammatory disorders, among others.
A Character Biosciences Inc. patent describes polypeptides acting as low-density lipoprotein receptor (LDLR) ligands and reported to be useful for the treatment of age-related macular degeneration (AMD).